<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1907">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01652495</url>
  </required_header>
  <id_info>
    <org_study_id>2012-000866-40</org_study_id>
    <nct_id>NCT01652495</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection</brief_title>
  <acronym>TPESP2011-12</acronym>
  <official_title>Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera San Giovanni Battista</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and effects on the
      hypothalamus-pituitary-adrenal axis of a single intrabursal injection of two different types
      of corticosteroids (methylprednisolone and triamcinolone) in patients with calcific shoulder
      tendinopathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rotator cuff calcific tendonitis is a common disease, mainly affecting women aged 30 to 50
      years old. It is associated to severe pain and impotence. US-guided percutaneous treatment
      is considered the gold standard treatment with the aim to destroy and wash out shoulder's
      calcification, responsible for inflammation, pain and functional limitation. Corticosteroids
      are injected in the subacromial-subdeltoid bursa at the end of the procedure to facilitate
      the prompt pain relief and functional recovery. Although corticosteroids represent the most
      powerful drugs to reduce inflammation and pain, their use is associated to important side
      effects, mainly the suppression of the hypothalamus-pituitary-axis (HPA). At the same time,
      no standardized protocols exist regarding the best type and dose of corticosteroid to be
      injected in association to the above mentioned treatment, nor data evaluating the exact
      duration of HPA suppression following a single intrabursal injection of corticosteroids.

      40 patients affected by rotator cuff calcific tendonitis will be enrolled in the study and
      randomly assigned to two groups: one group (20 patients) will be treated with a single
      intrabursal injection of 40 mg of methylprednisolone; the other group (20 patients) will be
      treated with a single intrabursal injection of 40 mg of triamcinolone.

      All patients will be tested at time 0 (morning before treatment) and at 1, 7, 15, 30 and 45
      days after the injection, using clinical, laboratory and US parameters in order to compare
      the efficacy and safety of the two drugs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Functional Improvement Measured According to Percentage Change in Constant Score</measure>
    <time_frame>180 days after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients will be evaluated clinically by Constant Score
Constant score: range 0 (total shoulder impairment) to 100 (non impaired shoulder). The score is obtained from two subjective (pain and relation between pain and daily-life activities) - and two objective physician-assessed (strength and range of motion) measurements
Reference: Constant CR and Murley AH. A clinical method of functional assessment of the shoulder. Clin Orthop Relat Res. 1987 Jan;(214):160-4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Suppression of Hypothalamus-pituitary-adrenal Axis</measure>
    <time_frame>45 days after treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Evaluation of blood cortisol and ACTH, free urinary cortisol, urinary levels of methylprednisolone or triamcinolone (depending on the administered drug) by RIA immunoassay and tandem mass assays
Persistent suppression of the HPA axis at the end of the follow up is based on the evidence of ACTH, plasmatic and urinary cortisol levels under reference values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Pain Severity Expressed as Percentage Change in VAS Score</measure>
    <time_frame>180 days after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>VAS score
VAS score is a 10 -cm graduated scale with scores ranging from 0 (no pain) to 10 (unbearable pain) self- reported by patients
Reference: Langley GB and Sheppeard H. The visual analogue scale: its use in pain measurement. Rheumatol Int 1985;5(4):145-148.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Tendinopathy</condition>
  <condition>Adrenal Insufficiency</condition>
  <arm_group>
    <arm_group_label>methylprednisolone acetate group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intrabursal injection of methylprednisolone acetate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triamcinolone acetonide group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intrabursal injection of Triamcinolone acetonide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone acetate</intervention_name>
    <description>Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate</description>
    <arm_group_label>methylprednisolone acetate group</arm_group_label>
    <other_name>Depo-medrol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide</description>
    <arm_group_label>Triamcinolone acetonide group</arm_group_label>
    <other_name>Triamvirgi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  painful rotator cuff calcific tendonitis demonstrated by ultrasounds

        Exclusion Criteria:

          -  pregnancy

          -  use of corticosteroids in the previous 2 months

          -  systemic chronic inflammatory or allergic diseases

          -  allergy to methylprednisolone or triamcinolone

          -  diabetes

          -  glaucoma

          -  coagulopathies or current treatment with antiaggregants or anticoagulants

          -  septic arthritis or infections

          -  calcific enthesopathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milva Battaglia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituti Ortopedici Rizzoli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rizzoli Orthopaedic Institute</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.ior.it/curarsi-al-rizzoli/drssa-milva-battaglia</url>
    <description>Dr Battaglia's page on the website of Rizzoli Orthopedic Institute explaining her activity</description>
  </link>
  <reference>
    <citation>Serafini G, Sconfienza LM, Lacelli F, Silvestri E, Aliprandi A, Sardanelli F. Rotator cuff calcific tendonitis: short-term and 10-year outcomes after two-needle us-guided percutaneous treatment--nonrandomized controlled trial. Radiology. 2009 Jul;252(1):157-64. doi: 10.1148/radiol.2521081816. Erratum in: Radiology. 2010 Feb;254(2):636.</citation>
    <PMID>19561254</PMID>
  </reference>
  <reference>
    <citation>Uhthoff HK, Loehr JW. Calcific Tendinopathy of the Rotator Cuff: Pathogenesis, Diagnosis, and Management. J Am Acad Orthop Surg. 1997 Jul;5(4):183-191.</citation>
    <PMID>10797220</PMID>
  </reference>
  <reference>
    <citation>Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA. 1999 Aug 18;282(7):671-6.</citation>
    <PMID>10517721</PMID>
  </reference>
  <reference>
    <citation>Spiegel RJ, Vigersky RA, Oliff AI, Echelberger CK, Bruton J, Poplack DG. Adrenal suppression after short-term corticosteroid therapy. Lancet. 1979 Mar 24;1(8117):630-3.</citation>
    <PMID>85870</PMID>
  </reference>
  <reference>
    <citation>Mader R, Lavi I, Luboshitzky R. Evaluation of the pituitary-adrenal axis function following single intraarticular injection of methylprednisolone. Arthritis Rheum. 2005 Mar;52(3):924-8.</citation>
    <PMID>15751089</PMID>
  </reference>
  <reference>
    <citation>Duclos M, Guinot M, Colsy M, Merle F, Baudot C, Corcuff JB, Lebouc Y. High risk of adrenal insufficiency after a single articular steroid injection in athletes. Med Sci Sports Exerc. 2007 Jul;39(7):1036-43.</citation>
    <PMID>17596769</PMID>
  </reference>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 23, 2014</lastchanged_date>
  <firstreceived_date>July 21, 2012</firstreceived_date>
  <firstreceived_results_date>March 22, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>milva.battaglia</investigator_full_name>
    <investigator_title>Clinician, Principal Investigator, Department of Radiology</investigator_title>
  </responsible_party>
  <keyword>rotatory cuff calcific tendonitis</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>US guided percutaneous treatment</keyword>
  <keyword>methylprednisolone</keyword>
  <keyword>triamcinolone</keyword>
  <keyword>hypothalamus pituitary adrenal axis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenal Insufficiency</mesh_term>
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Methylprednisolone Acetate Group</title>
          <description>Single intrabursal injection of methylprednisolone acetate
methylprednisolone acetate: Single intrabursal ultrasound guided injection</description>
        </group>
        <group group_id="P2">
          <title>Triamcinolone Acetonide Group</title>
          <description>Single intrabursal injection of Triamcinolone acetonide
Triamcinolone Acetonide: Single intrabursal ultrasound guided injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Methylprednisolone Acetate</title>
          <description>Single intrabursal injection of 40 mg (1 ml) of methylprednisolone acetate</description>
        </group>
        <group group_id="B2">
          <title>Triamcinolone Acetonide</title>
          <description>Single intrabursal injection of 40 mg (1 ml) of trimacinolone acetonide</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="51.05" spread="6.67"/>
                <measurement group_id="B2" value="46.35" spread="7.27"/>
                <measurement group_id="B3" value="48.70" spread="7.29"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="14"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="22"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Italy</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Functional Improvement Measured According to Percentage Change in Constant Score</title>
        <description>Patients will be evaluated clinically by Constant Score
Constant score: range 0 (total shoulder impairment) to 100 (non impaired shoulder). The score is obtained from two subjective (pain and relation between pain and daily-life activities) - and two objective physician-assessed (strength and range of motion) measurements
Reference: Constant CR and Murley AH. A clinical method of functional assessment of the shoulder. Clin Orthop Relat Res. 1987 Jan;(214):160-4.</description>
        <time_frame>180 days after treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Methylprednisolone Acetate Group</title>
            <description>Single intrabursal injection of methylprednisolone acetate
methylprednisolone acetate: Single intrabursal ultrasound guided injection</description>
          </group>
          <group group_id="O2">
            <title>Triamcinolone Acetonide Group</title>
            <description>Single intrabursal injection of Triamcinolone acetonide
Triamcinolone Acetonide: Single intrabursal ultrasound guided injection</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Functional Improvement Measured According to Percentage Change in Constant Score</title>
            <description>Patients will be evaluated clinically by Constant Score
Constant score: range 0 (total shoulder impairment) to 100 (non impaired shoulder). The score is obtained from two subjective (pain and relation between pain and daily-life activities) - and two objective physician-assessed (strength and range of motion) measurements
Reference: Constant CR and Murley AH. A clinical method of functional assessment of the shoulder. Clin Orthop Relat Res. 1987 Jan;(214):160-4.</description>
            <units>percentage of improvement Constant score</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="99" lower_limit="97" upper_limit="100"/>
                  <measurement group_id="O2" value="95" lower_limit="93" upper_limit="97"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Suppression of Hypothalamus-pituitary-adrenal Axis</title>
        <description>Evaluation of blood cortisol and ACTH, free urinary cortisol, urinary levels of methylprednisolone or triamcinolone (depending on the administered drug) by RIA immunoassay and tandem mass assays
Persistent suppression of the HPA axis at the end of the follow up is based on the evidence of ACTH, plasmatic and urinary cortisol levels under reference values</description>
        <time_frame>45 days after treatment</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Methylprednisolone Acetate Group</title>
            <description>Single intrabursal injection of methylprednisolone acetate
methylprednisolone acetate: Single intrabursal ultrasound guided injection</description>
          </group>
          <group group_id="O2">
            <title>Triamcinolone Acetonide Group</title>
            <description>Single intrabursal injection of Triamcinolone acetonide
Triamcinolone Acetonide: Single intrabursal ultrasound guided injection</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Suppression of Hypothalamus-pituitary-adrenal Axis</title>
            <description>Evaluation of blood cortisol and ACTH, free urinary cortisol, urinary levels of methylprednisolone or triamcinolone (depending on the administered drug) by RIA immunoassay and tandem mass assays
Persistent suppression of the HPA axis at the end of the follow up is based on the evidence of ACTH, plasmatic and urinary cortisol levels under reference values</description>
            <units>% of patients with HPA suppression</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Pain Severity Expressed as Percentage Change in VAS Score</title>
        <description>VAS score
VAS score is a 10 -cm graduated scale with scores ranging from 0 (no pain) to 10 (unbearable pain) self- reported by patients
Reference: Langley GB and Sheppeard H. The visual analogue scale: its use in pain measurement. Rheumatol Int 1985;5(4):145–148.</description>
        <time_frame>180 days after treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Methylprednisolone Acetate Group</title>
            <description>Single intrabursal injection of methylprednisolone acetate
methylprednisolone acetate: Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate</description>
          </group>
          <group group_id="O2">
            <title>Triamcinolone Acetonide Group</title>
            <description>Single intrabursal injection of Triamcinolone acetonide
Triamcinolone Acetonide: Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Reduction of Pain Severity Expressed as Percentage Change in VAS Score</title>
            <description>VAS score
VAS score is a 10 -cm graduated scale with scores ranging from 0 (no pain) to 10 (unbearable pain) self- reported by patients
Reference: Langley GB and Sheppeard H. The visual analogue scale: its use in pain measurement. Rheumatol Int 1985;5(4):145–148.</description>
            <units>percentage of pain reduction</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="82" lower_limit="73" upper_limit="91"/>
                  <measurement group_id="O2" value="96" lower_limit="87" upper_limit="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Methylprednisolone Acetate Group</title>
          <description>Single intrabursal injection of methylprednisolone acetate
methylprednisolone acetate: Single intrabursal ultrasound guided injection</description>
        </group>
        <group group_id="E2">
          <title>Triamcinolone Acetonide Group</title>
          <description>Single intrabursal injection of Triamcinolone acetonide
Triamcinolone Acetonide: Single intrabursal ultrasound guided injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Milva Battaglia, Director of Clinical Trials</name_or_title>
      <organization>Istituto Ortopedico Rizzoli</organization>
      <phone>0516366026 ext 0039</phone>
      <email>milva.battaglia@ior.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
